OR-PCI-SIG
11.1.2022 18:02:13 CET | Business Wire | Press release
PCI-SIG® , the organization responsible for the widely adopted PCI Express® (PCIe® ) standard, today announced the official release of the PCIe 6.0 specification, reaching 64 GT/s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005011/en/
PCIe 6.0 Specification Features
- 64 GT/s raw data rate and up to 256 GB/s via x16 configuration
- Pulse Amplitude Modulation with 4 levels (PAM4) signaling and leverages existing PAM4 already available in the industry
- Lightweight Forward Error Correct (FEC) and Cyclic Redundancy Check (CRC) mitigate the bit error rate increase associated with PAM4 signaling
- Flit (flow control unit) based encoding supports PAM4 modulation and enables more than double the bandwidth gain
- Updated Packet layout used in Flit Mode to provide additional functionality and simplify processing
- Maintains backwards compatibility with all previous generations of PCIe technology
PCI Express technology has served as the de facto interconnect of choice for nearly two decades. The PCIe 6.0 specification doubles the bandwidth and power efficiency of the PCIe 5.0 specification (32 GT/s), while providing low latency and reduced bandwidth overhead.
“PCI-SIG is pleased to announce the release of the PCIe 6.0 specification less than three years after the PCIe 5.0 specification,” said Al Yanes, PCI-SIG Chairperson and President. “PCIe 6.0 technology is the cost-effective and scalable interconnect solution that will continue to impact data-intensive markets like data center, artificial intelligence/machine learning, HPC, automotive, IoT, and military/aerospace, while also protecting industry investments by maintaining backwards compatibility with all previous generations of PCIe technology.”
“With the PCI Express SSD market forecasted to grow at a CAGR of 40% to over 800 exabytes by 2025, PCI-SIG continues to meet the future needs of storage applications,” said Greg Wong, Founder and Principal Analyst, Forward Insights. “With the storage industry transitioning to PCIe 4.0 technology and on the cusp of introducing PCIe 5.0 technology, companies will begin adopting PCIe 6.0 technology in their roadmaps to future-proof their products and take advantage of the high bandwidth and low latency that PCI Express technology offers.”
“There is a growing demand for ever-increasing performance in many segments in the data center such as high-performance computing and AI,” said Ashish Nadkarni, Group Vice President, Infrastructure Systems, Platforms and Technologies Group, IDC. “Within three to five years the application landscape will look very different and companies will likely begin updating their roadmaps accordingly. The advancement of an established standard like PCIe 6.0 architecture will serve the industry well in establishing composable infrastructure for performance intensive computing use cases.”
To learn more about PCI-SIG, visit www.pcisig.com . PCI-SIG members can download the full specification here .
Additional Resources
About PCI-SIG
PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of over 800 industry-leading member companies. To join PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com .
PCI-SIG, PCI Express, and PCIe are trademarks or registered trademarks of PCI-SIG. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005011/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
